IOSR Journal Of Pharmacy
(e)-ISSN: 2250-3013, (p)-ISSN: 2319-4219
Volume 14, Issue 11 Series. I (November 2024), PP. 01-12
www.iosrphr.org

"Advancements in Paclitaxel Formulation: The Role of Amorphous Solid Dispersion and Modern Excipients in Enhancing Drug Delivery"

[1] Devendra C. Sonawane [2] Rutik N. Liddad [3] Prof. Mrs Dipali Kothawade

Received 14 November 2024; Accepted 27 November 2024

ABSTRACT :-Amorphous Solid Dispersion (ASD) technology has emerged as a promising strategy to enhance the solubility and bioavailability of poorly water-soluble drugs, such as Paclitaxel, a key agent in cancer therapy. Despite its significant antitumor activity against various malignancies, Paclitaxel's clinical application has been hampered by its low solubility and adverse effects associated with its conventional formulation, which utilizes Cremophor® EL. This review highlights recent advancements in ASD formulations aimed at improving Paclitaxel delivery through innovative polymer systems, nanotechnology, and advanced manufacturing techniques such as spray drying and hot melt extrusion. The incorporation of novel polymers and the development of co-amorphous systems have demonstrated improved stability and dissolution rates, while nanoparticle-based ASDs have shown potential for targeted drug delivery, thereby reducing systemic toxicity. Characterization techniques, including X-ray Powder Diffraction (XRPD), thermal analysis, and spectroscopy, are essential for understanding the molecular behavior of ASDs and ensuring product stability. Furthermore, the mechanism of absorption for ASD formulations relies on passive diffusion, where enhanced solubility maintains a supersaturated state conducive to improved bioavailability. This review underscores the importance of ASDs in the pharmaceutical formulation of Paclitaxel and similar drugs, suggesting a significant avenue for improving cancer therapy.

KEYWORDS :- Amorphous Solid Dispersion (ASD), Paclitaxel, Solubility, Bioavailability, Polymer, Drug delivery, Passive diffusion, Cancer therapy.

CONSIDERATIONS :-

Many pharmaceutical drugs face challenges with poor water solubility, which can limit their bioavailability and therapeutic efficacy. Here are examples of some poorly water-soluble drugs:-

1. Ibuprofen– A widely used nonsteroidal anti-inflammatory drug (NSAID).
2. Griseofulvin – An antifungal drug.
3. Itraconazole – Another antifungal medication used for systemic infections.
4. Paclitaxel – A chemotherapy drug used to treat various cancers.
5. Fenofibrate– Used to reduce cholesterol levels.
6. Ritonavir– An antiretroviral drug for treating HIV.
7. Phenytoin – An anticonvulsant for treating epilepsy.
8. Nifedipine– A calcium channel blocker used to treat high blood pressure and angina.

Formulation strategies such as nanoparticle delivery systems, solid dispersions, or lipid-based formulations are often employed to overcome the solubility challenges of these drugs.

One These Drug i.e **Paclitaxel**

I. INTRODUCTION :-

Paclitaxel is a chemotherapy drug used to treat various types of cancer, including ovarian, breast, lung, cervical, and pancreatic cancer. It's also used to treat Kaposi's sarcoma, a type of cancer that affects people with AIDS.

Paclitaxel is an important chemotherapy drug used to treat various types of cancer. Below is a detailed overview:

General Information's :-

- **Drug Name**: Paclitaxel

- **Structure:**



Empirical formula: $C_{47}H_{51}NO_{14}$
Molecular weight: 853.9 g/mol
Average mass: 853.9 Da
Systemic name: (2α, 5β, 7β, 10β, 13α)-4,10-Diacetoxy-13-{[(2R, 3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate

- **Brand Names**: Taxol, Onxol, Abraxane (albumin-bound formulation)
- **Drug Class**: Taxane (antimicrotubule agent)
- **Discovery**: Isolated from the bark of the Pacific yew tree (Taxus brevifolia) in the 1960s.
- **Formulations:**

Traditional (cremophor-based): Taxol
Albumin-bound (less toxic): Abraxane

- **Mechanism of Action**

Paclitaxel works by disrupting the microtubule function during cell division:
Microtubule Stabilization: It binds to the β-tubulin subunit of microtubules, preventing them from disassembling, which halts the process of cell division (mitosis).
Cell Death: By stabilizing microtubules, paclitaxel stops the cancer cells from completing mitosis, ultimately leading to programmed cell death (apoptosis).

- **Pharmacokinetics**

Absorption: Given intravenously; not absorbed orally.
Metabolism: Primarily metabolized in the liver by CYP450 enzymes (CYP2C8 and CYP3A4).
Excretion: Mainly excreted through feces, with a small amount through urine.

- **Special Considerations**

Pregnancy and Lactation: Paclitaxel is contraindicated during pregnancy due to its teratogenic effects. Women should avoid becoming pregnant while receiving the drug.
Elderly Patients: Dose adjustments may be required due to decreased metabolism and increased sensitivity to side effects.
Liver Function: Paclitaxel is metabolized in the liver, so patients with hepatic impairment may require dose reductions or more frequent monitoring.

-Paclitaxel is still widely used today, particularly in the treatment of various cancers. It is typically used in its conventional form or as part of newer formulations to improve its efficacy and reduce side effects.

Here are the common forms and routes of administration:

1. Conventional Formulation (Injectable Solution)

- Route:Intravenous (IV) infusion
- Form: Paclitaxel is commonly administered as an injectable solution, typically combined with solvents such as Cremophor EL (a surfactant) and ethanol to enhance its solubility. This formulation is known as *Taxol*.
- Use: This form of Paclitaxel is administered for the treatment of various cancers, including:

- Breast cancer
- Ovarian cancer
- Lung cancer (non-small cell lung cancer)
- Kaposi's sarcoma (in HIV-positive patients)

Challenges: The use of solvents like Cremophor EL can cause hypersensitivity reactions in some patients, requiring premedication with steroids and antihistamines to minimize these side effects.

2. Albumin-Bound Paclitaxel (Nanoparticle Formulation)

- Route:Intravenous (IV) infusion
- Form: A newer formulation known as nab-paclitaxel brand name: Abraxaney is an albumin-bound nanoparticle form of Paclitaxel. This formulation does not require toxic solvents, thereby reducing hypersensitivity reactions.
- Nab-paclitaxel is used for:

-Metastatic breast cancer
-Non-small cell lung cancer
-Pancreatic cancer

- Advantages : The nanoparticle formulation improves the delivery of Paclitaxel to the tumor, enhances solubility, and minimizes the need for premedication.

3. Oral Paclitaxel

- Route: Oral administration (in clinical trials or limited use)
- Form: Traditionally, Paclitaxel is not orally bioavailable due to its poor solubility and high first-pass metabolism in the liver. However, recent advancements are exploring oral Paclitaxel formulations combined with absorption enhancers like *HM30181A*, a P-glycoprotein inhibitor.
- Use: Oral Paclitaxel is still under investigation in clinical trials but has shown promise for the treatment of advanced breast cancer and other solid tumors.
- Advantages: An oral form would significantly improve patient comfort and compliance, offering an alternative to IV infusions.

4. Intraperitoneal Paclitaxel

- Route: Intraperitoneal (IP) administration.
- Form: Paclitaxel can also be administered intraperitoneally, which involves delivering the drug directly into the peritoneal cavity.
- Use: This method is particularly used in patients with advanced ovarian cancer that has spread within the abdominal cavity.
- Advantages: Direct administration into the peritoneal cavity increases the concentration of Paclitaxel in the area where the tumors are located, potentially improving outcomes while reducing systemic side effects.

5. Topical Paclitaxel

- Route:Topical administration
- Form: Topical formulations of Paclitaxel are being studied for localized applications, especially in non-cancerous conditions or skin-related cancers such as cutaneous Kaposi's sarcoma.
- Use: Limited use in clinical trials, particularly for dermatological cancers.
- Advantages: Localized treatment with reduced systemic toxicity.

FUTURE DIRECTIONS

- **Amorphous Solid Dispersion (ASD)** : Although ASD technology is widely used to improve the solubility of poorly water-soluble drugs, Paclitaxel ASD formulations are still under research, primarily focusing on oral delivery methods or enhanced injectable formulations.

Paclitaxel remains a cornerstone drug in cancer therapy, with ongoing research aimed at improving its delivery and reducing its side effects.

Paclitaxel is a hydrophobic antineoplastic agent demonstrating significant antitumor activity against a broad spectrum of human malignancies, including breast, lung, and ovarian cancer. Following the identification of paclitaxel as the active ingredient in crude ethanolic extracts of the bark of the Pacific yew tree, Taxus brevifolia, development of this drug was suspended for over a decade because of problems in drug formulation, drug supply, and controversies regarding the mechanism of action (CitationWani et al 1971).

After investigation of a large variety of excipients to enable parenteral administration of paclitaxel, the formulation approach using the polyoxyethylated castor oil derivative Cremophor® EL (CrEL) represented the most viable option (CitationAdams et al 1993). Currently, paclitaxel is commercially marketed in a formulation that contains a solvent system of CrEL and dehydrated ethanol. CrEL is widely used as a vehicle for the solubilization of a number of other hydrophobic drugs including anesthetics, vitamins, sedatives, photosensitizers, immunosuppressants, and investigational anticancer drugs. The amount of CrEL in Taxol® per administration is relatively high, and therefore its toxicological and pharmacological behavior in the context of

chemotherapeutic treatment with paclitaxel is of major importance (CitationGelderblom et al 2001; Citationvan Zuylen, Verweij, et al 2001).



Fig no.01 :- Concept of ASD

WHAT IS ASD'S ?

Amorphous solid dispersion (ASD) is a formulation strategy used in pharmaceutics to improve the solubility and bioavailability of poorly water-soluble drugs. Many drugs exhibit poor solubility, which can limit their absorption in the body, making it difficult for them to achieve therapeutic concentrations.

ASDs are used in many drugs, including those that treat cancer, cystic fibrosis, and organ transplant rejection.

Definition:

In an amorphous solid dispersion, the active pharmaceutical ingredient (API) is dispersed in a polymeric matrix in an amorphous (non-crystalline) form. Unlike the crystalline form, where molecules are packed in an orderly structure, the amorphous form lacks this regularity, which generally makes the drug more soluble.

Here are some characteristics of ASDs:

- How they work

ASDs are a molecular mixture of poorly soluble drugs and hydrophilic carriers that reduce the size of the drug particles to a molecular level. This helps the drug dissolve or co-dissolve in the carriers.

- How they're made

ASDs can be made using a variety of methods, including solvent evaporation, melting, fused deposition modeling, and electrospinning.

- How they benefit patients

ASDs improve the dissolution rate and release performance of drugs, making them easier for the body to absorb. They also reduce the effect of food on the drug, so it works equally well whether a patient is fasting or eating.

Components:

1. Active Pharmaceutical Ingredient (API): The drug in its amorphous form.
2. Polymer: A carrier material that helps stabilize the amorphous form of the drug and prevents it from crystallizing. Common polymers include:
   - Hydroxypropyl methylcellulose (HPMC)
   - Polyvinylpyrrolidone (PVP)
   - Polyethylene glycol (PEG)

Benefits of ASD in Pharmaceutics:

1. Increased Solubility: The amorphous form of a drug has higher free energy and greater solubility compared to its crystalline form, making it easier for the drug to dissolve in bodily fluids.

2. Enhanced Bioavailability: With better solubility, more drug molecules are available for absorption, leading to increased bioavailability.
3. Stability: The polymer matrix helps prevent the drug from crystallizing over time, maintaining its amorphous state and ensuring consistent performance throughout its shelf life.
4. Improved Drug Release: The dispersion can be tailored to control the release rate of the drug, providing sustained or immediate release as needed for therapeutic effect.

How it Helps:-

- Poorly Water-Soluble Drugs: ASD is particularly useful for drugs with poor water solubility (Biopharmaceutics Classification System [BCS] Class II and IV). Many modern drugs fall into this category, so ASDs provide a way to overcome the limitations of low solubility.
- Therapeutic Efficacy: By enhancing solubility and bioavailability, ASD can improve the therapeutic efficacy of drugs, ensuring that patients receive the intended dose effectively.
- Reduced Dose Requirements: With better absorption, lower doses of the drug may be required to achieve the same therapeutic effect, potentially reducing side effects and improving patient compliance.

Paclitaxel is essential in cancer treatment, often used when other treatments have failed. Regular monitoring is required during treatment to manage side effects.

❖ **Recent Developments in Paclitaxel and Amorphous Solid Dispersions (ASD)**

Paclitaxel is a chemotherapy drug with very poor water solubility, which has led to the development of various strategies to enhance its bioavailability, including Amorphous Solid Dispersion (ASD).
Here are some of the recent advancements and findings related to Paclitaxel and its formulation using ASD:

1. New Polymer Systems for ASD of Paclitaxel :-

- Researchers are exploring new polymeric carriers for ASD formulations to improve the stability and dissolution rate of Paclitaxel. For instance, newer polymers such as **Hydroxypropyl methylcellulose acetate succinate (HPMCAS)** and **Polyvinylpyrrolidone (PVP)** have shown promising results in increasing the solubility and bioavailability of Paclitaxel.
- These polymer systems create a stable amorphous form of the drug, preventing crystallization during storage and after oral administration, which is crucial for ensuring consistent therapeutic outcomes.

2. Nanotechnology in ASD Formulations :-

- Nanoparticle-based ASDs have also gained attention. By combining Paclitaxel with nanocarriers (e.g.,polymeric nanoparticles), the drug is better dispersed at the molecular level. This approach helps maintain the amorphous state and increases the surface area for drug dissolution, further enhancing absorption.
- Nanoparticle-ASD formulations show potential in reducing the systemic toxicity of Paclitaxel by enabling more targeted drug delivery to cancer cells.

3. Co-Amorphous Systems :-

- Another emerging trend is the development of co-amorphous systems where Paclitaxel is combined with a small molecule or another drug, stabilizing the amorphous form through intermolecular interactions. This approach has shown significant improvements in the solubility and stability of Paclitaxel in ASD formulations.

4. Spray Drying and Hot Melt Extrusions :-

- New advancements in manufacturing techniques such as spray drying and hot melt extrusion are being used to produce Paclitaxel ASDs. These techniques allow for precise control over the particle size and drug-polymer interaction, which further enhances drug dissolution.
- Spray-dried dispersions, in particular, have shown to improve the dissolution rate and bioavailability of Paclitaxel compared to traditional crystalline formulations.



Fig no. 02

Solubility is one of the problems in drug formulation, particularly for oral dosage forms, which hardly dissolve in gastrointestinal fluids. Furthermore, it can be classified into four classes according to the Biopharmaceutical Classification System (BCS). Four classes of BCS show solubility and permeability, as shown in Figure 1. In class II, modifications such as solid dispersion, particle size reduction, and nanoparticles are employed to improve solubility.



Fig No. 03 :- BCS Classification

The drug In an amorphous form can be transformed into an amorphous solid dispersion, thereby improving its bioavailability. In this process, the polymer carrier played an important role by increasing the

dissolution rate, enhancing drug solubility, and improving the physical stability of the solid state. Additionally, it can reduce molecular mobility and raise the glass transition temperature, resulting in increased stability during the conversion from a crystalline into amorphous form. The drug–polymer interaction contributed to the stabilization by disrupting the intermolecular interaction between the drug crystal lattice. The presence of the polymer alters the nature of the crystal lattice, which in turn affects the stability of the amorphous solid dispersion. The enhancement of bioavailability in this approach was driven by both thermodynamic and kinetic forces.

Characterization of ASD:-

In-depth analysis of these formulations was necessary due to the characteristics of ASDs and the potential risk of recrystallization. Given the complexity involved, a diverse range of complementary techniques is often required. This is because no single characterization methodology can provide all the necessary information.

- X-ray Powder Diffraction (XRPD)

An essential tool for characterizing amorphous solid dispersions was powder X-ray diffraction.
This method was used to confirm the presence of the drug in its amorphous state within the solid dispersion.
Recent developments in XRPD instrumentation and software have significantly contributed to a better understanding of the molecular behavior of amorphous drugs in amorphous solid dispersion under stressed conditions. For example, XRPD equipped with variable temperature (VT) or humidity control has proven valuable in providing information under non-ambient conditions.
Zhu et al. employed in situ small-angle/wide-angle X-ray scattering to investigate the crystallization kinetics of a naproxen ASD system at various temperatures.
Additionally, there has been an increased recognition of the significance of utilizing the atomic pairwise distribution function to measure the degree of amorphization caused by crystalline drugs.
Nollenberger et al. demonstrated the impact of minor modifications to polymer structure at the molecular level on the release characteristics of the finished product using pairwise distribution function analysis.

- Thermal Analysis

DSC and thermogravimetric analyses were the two most frequently employed thermal analyses (TAs). However, dynamic mechanical analysis and isothermal microcalorimetry were utilized in the pharmaceutical sector for regular examination. These cutting-edge TA techniques, including DSC, offer valuable insight into various molecular processes that take place in the solid dispersion, such as glass transition, polymorphic transition, crystallization, structural relaxation, molecular mobility, as well as miscibility between drug and polymer.
Tg and heat capacity analyses were applied by Mahajan et al. to measure the amount of amorphous material present in carvedilol tablets.
Additionally, the increased sensitivity of fast-scan DSC allows for the separation of overlapping thermal events, providing an additional advantage [195]. Differential mechanical thermal analysis offers a means to explore the relaxation transitions, the viscoelastic properties of polymers, and miscibility in binary or ternary systems.
The development of Increasingly advanced sensors in recent years has made real-time solid-state characterization, as a function of temperature change, achievable. With the use of methods such as VT-XRPD, VT molecular spectroscopy, and VT-ssNMR, amorphous drugs' molecular orientation, structural relaxation in ASD systems, and their interaction with polymers were examined in greater depth. In particular, the localized TA technique known as nano-TA, when combined with atomic force microscopy, can produce high-resolution images of the thermal behavior of amorphous drugs. Incorporating a tiny heater with a topographic resolution of around 5 nm onto a microfabricated silicon-based probe enabled the measurement of thermal characteristics at a nanometer scale.

- Spectroscopy

Among the vibrational spectroscopic techniques, Fourier transformed IR spectroscopy and Raman spectroscopy, when combined with attenuated total reflectance and/or diffuse reflectance, have proven to be the most effective.
These approaches have been applied in the pharmaceutical industry for a variety of purposes, including phase transition, polymorph identification, recrystallization stability, evaluation of various manufacturing processes for solid dispersions, phase separation, and the type and degree of drug–polymer interaction.
By investigating band vibrations, these methods provided details on structural and molecular conformation in the solid state. Furthermore, the interior structure of molecules and crystals can be identified using the potent light-scattering technique known as Raman spectroscopy. Studying the low-energy lattice vibrations connected to various crystal packing configurations provided information into the crystal packing.
Raman spectroscopy has been employed by Furuyama et al., as a mapping tool to differentiate between troglitazone's crystalline and amorphous forms in solid dispersions.
Sinclair et al., utilized FT Raman spectroscopy to study the recrystallization kinetics of an amorphous solid dispersion of ibipinabant.

Additionally, it was applied for the identification of trace crystallinity that could have been missed by XRPD or high-sensitivity DSC.

- Water Vapor Sorption

Water vapor sorption has frequently been used to investigate the behavior of crystalline and amorphous materials when exposed to moisture. To evaluate the moisture sorption data and gain understanding into drug polymer-water interactions, ternary FH interaction theory was employed. Furthermore, when combined with other methods such as DSC, Fourier transform IR spectroscopy, and nuclear magnetic resonance (NMR), it provided a variety of data on molecular level attributes such as degree of amorphization, surface properties, phase transitions, critical relative humidity for glass transition and crystallization, as well as physical stability of materials.

The combination of near IR spectroscopy with dynamic vapor sorption allows for an understanding of the desorption behavior of amorphous drugs before and during its crystallization, as a function of temperature and relative humidity.

- Solid-State Nuclear Magnetic Resonance

ssNMR is a nondestructive method that provides information about amorphous solid dispersions in both qualitative and quantitative forms, and it offers comprehensive one- and two-dimensional structural data based on NMR relaxometry, spectroscopy, and imaging .

The size of the drug polymer domain in solid dispersions was predicted by correlating the relaxation period with the length scale of the spin diffusion. For instance, the spin–lattice relaxation time, T1, had values in the range of 1 to 5 s, which equated to a domain size of about 20–50 nm. T1r (spin–spin relaxation time) values between 5 and 50 ms suggested a length scale of approximately 2–5 nm. These relaxation time measurements allowed for accurate forecasts. A single value of 1 H T1 and T1r in amorphous solid dispersions indicates a domain smaller than 2–5 nm. A size of about 5–20 nm was exhibited by several T1r values but the same T1 value. For drugs and polymers, domain sizes greater than 20–50 nm result in distinct T1 and T1r values. Compared to DSC which only provided single Tg values for domain sizes smaller than 20–30 nm, this approach is substantially more sensitive. To improve the stability of amorphous solid dispersions and prevent phase separation during the product's shelf life, ssNMR relaxometry better comprehended drug–polymer intimacy in the solid dispersion and preventing phase separation .

1H transverse magnetization relaxation T2 measurements provided information regarding the phase composition and mobility of polymer molecules in solid dispersions [212]. Meanwhile, 13C cross-polarization magic angle spinning NMR experiments were used when no differences were observed in the XRPD pattern.

Additionally, NMR tests were utilized to investigate the recrystallization of amorphous troglitazone in solid dispersions made using various techniques. A useful complement to analytical techniques for analyzing the kinetics of polymer mobilization and water penetration was the NMR microimaging approach .

- Inverse Gas Chromatography

A developing method, inverse gas chromatography, has been utilized to examine the surface characteristics of amorphous solid dispersions.

This technique was employed to investigate molecular mobility, amorphous transition or recrystallization, and molecular relaxation. Furthermore, it is particularly needed for the identification of batch-to-batch variation in amorphous solid dispersions using the same or different techniques.

A study of the increased molecular mobility on a material's surface compared to its bulk provided insight on the interactions between moisture and the recrystallization of amorphous drugs.

Inverse gas chromatography was employed by Hasegawa et al. to explore structural relaxation at the surface of solid dispersions.

Furthermore, it was discovered that structural relaxation occurs more quickly at the surface than in the bulk due to increased molecular mobility. The kinetics of crystallization on the surface of solid dispersions were used to predict the physical

ASD for Cancer therapy :-

Despite paclitaxel belonging to BCS class 4, it has also been used to treat cancer. Moes et al. developed an oral dosage form of paclitaxel as an amorphous solid dispersion using the freeze-drying process and PVP K30 as a carrier. The formulation boosts the dissolving rate, provides superior solubility, and prevents crystallization. Polymer PVP primarily inhibited crystallization and promoted solubility, while SLS improved wettability, thereby accelerating dissolution. The amorphous solid dispersion of paclitaxel, known as ModraPac001 10 mg, was formulated as a capsule for clinical studies and exhibited (nearly) the same pharmacokinetic characteristics as the premix solution of low-dosage paclitaxel, which was already utilized for anticancer therapy.

Liu et al. developed an oral formulation of RA-XII in order to create a therapeutically effective anticancer drug. However, due to poor solubility and limited permeability, RA-XII demonstrated minimal oral

bioavailability in mice. For effective distribution of this drug by oral administration, Liu et al. employed a natural deep eutectic solvent (NADES) in the investigation. The technique employed was amorphous solid dispersion utilizing PVP polymer. This formulation enhanced cytotoxicity in vitro, dissolution rate, perceived solubility, and homogeneity. When compared to pure RA-XII in 0.5% CMC-Na, the oral bioavailability of this drug in NADES and ASD solutions was increased by approximately 11.58 and 7.56 times, respectively. According to pharmacokinetic studies conducted in vivo, the ASD of RA-XII inhibited cell proliferation of all RKOs more effectively than free RA-XII. The therapeutic effect of RA-XII was more pronounced in cases with severe basal cancer when formulated as an ASD.



Fig no. 04

II. DISCUSSION

Crucial challenge in the uptake of dissolved ASD was the absorption of anticancer drug particles that were molecularly dispersed. Previous study reported that the absorption of poorly water-soluble drugs, including anticancer medications, was enhanced only when API was in a supersaturated state.

Meanwhile, the presence of solubilized API, such as micelles from endogenous bile salts or surfactants in the formulation, impeded the transport of anticancer drugs.

The mechanism of drug absorption commonly occurred by passive diffusion. Based on the Fick law of diffusion, the drugs will move due to the concentration gradient from a higher concentration to a lower concentration of drugs until equilibrium is reached. In the case of drug absorption, the soluble drug in the aqueous compartment of the body, such as interstitial space, will move through aqueous pores in the endothelium of blood vessels. Thus, the solubility of the drug in the aqueous compartment of the body significantly affects the amount of drug absorption via passive diffusion. The drug absorption of anticancer drugs crystal could be lower compared to that amorphous state due to their poor water solubility. Meanwhile, in the ASD of anticancer drugs, the amount of drug absorption would be higher because the solubility of drugs was improved and the supersaturated solution in the aqueous compartment of the body was maintained by the intermolecular interaction of drug and polymer .

According to studies, the transport mechanisms are passive diffusion, which had been demonstrated to improve in vivo bioavailability .

Shi et al. Reported that the concentration of molecularly soluble drugs in the release medium was not significantly affected by the increase in solubility of the drug by micellization. This suggested that only higher concentrations of molecularly dissolved drugs (true supersaturation) were significant for increased permeation rates.

As a result, it was assumed that the absorption of poorly water-soluble drugs (including anticancer drugs) in the ASD formulation was mainly passive diffusion where only molecularly dissolved API was considerably absorbed by the intestinal epithelium. Furthermore, the permeability could only be enhanced by high concentrations of dispersed API. Therefore, drug absorption from dissolved ASD appears to be primarily driven by passive diffusion, which could be augmented by increasing the concentration of molecularly dissolved API, with the solubility of the amorphous drug being the limiting factor. Improving the bioavailability of poorly water-soluble anticancer drugs could also enhance their pharmacokinetics, efficacy, and safety. The speculated mechanism of bioavailability improvement from amorphous anticancer drugs in amorphous solid dispersion is summarised in figure Below …..



Fig no. 04

III. CONCLUSION :-

The development of Amorphous Solid Dispersion (ASD) formulations represents a pivotal advancement in the delivery of poorly water-soluble drugs like Paclitaxel. By leveraging novel polymeric carriers and innovative manufacturing techniques, ASDs have the potential to significantly enhance the solubility, bioavailability, and therapeutic efficacy of these drugs, addressing critical challenges in cancer treatment. Continued research and characterization of ASDs will further elucidate their mechanisms of action and stability, leading to improved formulations that maximize the therapeutic benefits of Paclitaxel and other similar agents. Ultimately, the integration of ASD technology into cancer therapy can enhance patient outcomes by ensuring more effective and safer drug delivery. By focusing on the emerging techniques and technologies, a research view on Paclitaxel ASD can lead to significantly improved cancer treatments with fewer side effects.

References:

[1]. Paclitaxel ASD formulation in Nanotechnology (https://www.sciencedirect.com/science/article/abs/pii/S093964111930479X)
[2]. Amorphous Solid Dispersion of Paclitaxel (https://link.springer.com/article/10.1007/s11095-010-0174-2)
[3]. Recent Advances in ASD for Chemotherapy Drugs (https://www.mdpi.com/1999-4923/13/2/168)
[4]. Baghel, S.; Cathcart, H.; O'Reilly, N.J. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs. J. Pharm. Sci. 2016, 105, 2527–2544. [Google Scholar] [CrossRef] [PubMed] [Green Version]
[5]. Vo, C.L.-N.; Park, C.; Lee, B.-J. Current Trends and Future Perspectives of Solid Dispersions Containing Poorly Water-Soluble Drugs. Eur. J. Pharm. Biopharm. **2013**, 85, 799–813. [**Google Scholar**] [**CrossRef**] [**PubMed**]
[6]. Liu, M.; Lai, Z.; Zhu, L.; Ding, X.; Tong, X.; Wang, Z.; Bi, Q.; Tan, N. Novel Amorphous Solid Dispersion Based on Natural Deep Eutectic Solvent for Enhancing Delivery of Anti-Tumor RA-XII by Oral Administration in Rats. Eur. J. Pharm. Sci. 2021, 166, 105931. [Google Scholar] [CrossRef] [PubMed]
[7]. Kumar, V.; Mintoo, M.J.; Mondhe, D.M.; Bharate, S.B.; Vishwakarma, R.A.; Bharate, S.S. Binary and Ternary Solid Dispersions of an Anticancer Preclinical Lead, IIIM-290: In Vitro and In Vivo Studies. Int. J. Pharm. 2019, 570, 118683. [Google Scholar] [CrossRef]
[8]. Buckley, S.T.; Frank, K.J.; Fricker, G.; Brandl, M. Biopharmaceutical Classification of Poorly Soluble Drugs with Respect to "Enabling Formulations". Eur. J. Pharm. Sci. 2013, 50, 8–16. [Google Scholar] [CrossRef] [Green Version]
[9]. Ma, Y.; He, H.; Fan, W.; Li, Y.; Zhang, W.; Zhao, W.; Qi, J.; Lu, Y.; Dong, X.; Wu, W. In Vivo Fate of Biomimetic Mixed Micelles as Nanocarriers for Bioavailability Enhancement of Lipid-Drug Conjugates. ACS Biomater. Sci. Eng. 2017, 3, 2399–2409. [Google Scholar] [CrossRef] [PubMed]
[10]. Alagga, A.A.; Gupta, V. Drug Absorption. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557405/ (accessed on 1 August 2023).
[11]. Deng, L.; Wang, Y.; Gong, T.; Sun, X.; Zhang, Z.-R. Dissolution and Bioavailability Enhancement of Alpha-Asarone by Solid Dispersions via Oral Administration. Drug Deliv. Ind. Pharm. 2017, 43, 1817–1826. [Google Scholar] [CrossRef]
[12]. Shi, C.; Tong, Q.; Fang, J.; Wang, C.; Wu, J.; Wang, W. Preparation, Characterization and In Vivo Studies of Amorphous Solid Dispersion of Berberine with Hydrogenated Phosphatidylcholine. Eur. J. Pharm. Sci. 2015, 74, 11. [Google Scholar] [CrossRef]

[13]. Fong, S.Y.K.; Martins, S.M.; Brandl, M.; Brandl, A.B. Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-In Vitro Permeability Enhancement. J. Pharm. Sci. 2016, 105, 1113–1123. [Google Scholar] [CrossRef]

[14]. Jacobsen, A.-C.; Elvang, P.A.; Brandl, A.B.; Brandl, M. A Dynamic In Vitro Permeation Study on Solid Mono- and Diacyl-Phospholipid Dispersions of Celecoxib. Eur. J. Pharm. Sci. 2019, 127, 199–207. [Google Scholar] [CrossRef] [Green Version]

[15]. Ueda, K.; Higashi, K.; Kataoka, M.; Yamashita, S.; Yamamoto, K.; Moribe, K. Inhibition Mechanism of Hydroxypropyl Methylcellulose Acetate Succinate on Drug Crystallization in Gastrointestinal Fluid and Drug Permeability from a Supersaturated Solution. Eur. J. Pharm. Sci. 2014, 62, 293–300. [Google Scholar] [CrossRef]

[16]. Engers, D.; Teng, J.; Jimenez-Novoa, J.; Gent, P.; Hossack, S.; Campbell, C.; Thomson, J.; Ivanisevic, I.; Templeton, A.; Byrn, S.; et al. A Solid-State Approach to Enable Early Development Compounds: Selection and Animsal Bioavailability Studies of an Itraconazole Amorphous Solid Dispersion. J. Pharm. Sci. 2010, 99, 3901–3922. [Google Scholar] [CrossRef]

[17]. Al-Obaidi, H.; Lawrence, M.J.; Al-Saden, N.; Ke, P. Investigation of Griseofulvin and Hydroxypropylmethyl Cellulose Acetate Succinate Miscibility in Ball Milled Solid Dispersions. Int. J. Pharm. 2013, 443, 95–102. [Google Scholar] [CrossRef] [PubMed]

[18]. Moes, J.; Koolen, S.; Huitema, A.; Schellens, J.; Beijnen, J.; Nuijen, B. Development of an Oral Solid Dispersion Formulation for Use in Low-Dose Metronomic Chemotherapy of Paclitaxel. Eur. J. Pharm. Biopharm. 2013, 83, 87–94. [Google Scholar] [CrossRef] [PubMed]

[19]. Zhao, Y.; Xin, T.; Ye, T.; Yang, X.; Pan, W. Solid Dispersion in the Development of a Nimodipine Delayed-Release Tablet Formulation. Asian J. Pharm. Sci. 2014, 9, 35–41. [Google Scholar] [CrossRef] [Green Version]

[20]. Chauhan, A. Powder XRD Technique and Its Applications in Science and Technology. J. Anal. Bioanal. Tech. 2014, 5, 212. [Google Scholar] [CrossRef] [Green Version]

[21]. Zhu, Q.; Toth, S.J.; Simpson, G.J.; Hsu, H.-Y.; Taylor, L.S.; Harris, M.T. Crystallization and Dissolution Behavior of Naproxen/Polyethylene Glycol Solid Dispersions. J. Phys. Chem. B 2013, 117, 1494–1500. [Google Scholar] [CrossRef] [PubMed]

[22]. Bøtker, J.P.; Karmwar, P.; Strachan, C.J.; Cornett, C.; Tian, F.; Zujovic, Z.; Rantanen, J.; Rades, T. Assessment of Crystalline Disorder in Cryo-Milled Samples of Indomethacin Using Atomic Pair-Wise Distribution Functions. Int. J. Pharm. 2011, 417, 112–119. [Google Scholar] [CrossRef] [PubMed]

[23]. Nollenberger, K.; Gryczke, A.; Meier, C.; Dressman, J.; Schmidt, M.U.; Brühne, S. Pair Distribution Function X-ray Analysis Explains Dissolution Characteristics of Felodipine Melt Extrusion Products. J. Pharm. Sci. 2009, 98, 1476–1486. [Google Scholar] [CrossRef]

[24]. Baird, J.A.; Taylor, L.S. Evaluation of Amorphous Solid Dispersion Properties Using Thermal Analysis Techniques. Adv. Drug Deliv. Rev. 2012, 64, 396–421. [Google Scholar] [CrossRef]

[25]. Raut, D.M.; Sakharkar, D.M.; Bodke, P.S.; Mahajan, D.T. Determination of Traces of Amorphous Carvidilol Content in Carvedilol Drug Substance and Drug Product Using Modulated Differential Scanning Colorimetry. Pharm. Lett. 2011, 3, 1–12. [Google Scholar]

[26]. Ford, J.L.; Mann, T.E. Fast-Scan DSC and Its Role in Pharmaceutical Physical Form Characterisation and Selection. Adv. Drug Deliv. Rev. 2012, 64, 422–430. [Google Scholar] [CrossRef]

[27]. Jones, D.S.; Tian, Y.; Abu-Diak, O.; Andrews, G.P. Pharmaceutical Applications of Dynamic Mechanical Thermal Analysis. Adv. Drug Deliv. Rev. 2012, 64, 440–448. [Google Scholar] [CrossRef] [PubMed]

[28]. Zhang, J.; Bunker, M.; Chen, X.; Parker, A.P.; Patel, N.; Roberts, C.J. Nanoscale Thermal Analysis of Pharmaceutical Solid Dispersions. Int. J. Pharm. 2009, 380, 170–173. [Google Scholar] [CrossRef] [PubMed]

[29]. Ewing, A.V.; Clarke, G.S.; Kazarian, S.G. Stability of Indomethacin with Relevance to the Release from Amorphous Solid Dispersions Studied with ATR-FTIR Spectroscopic Imaging. Eur. J. Pharm. Sci. 2014, 60, 64–71. [Google Scholar] [CrossRef] [PubMed]

[30]. Forster, A.; Hempenstall, J.; Rades, T. Characterization of Glass Solutions of Poorly Water-Soluble Drugs Produced by Melt Extrusion with Hydrophilic Amorphous Polymers. J. Pharm. Pharmacol. 2010, 53, 303–315. [Google Scholar] [CrossRef] [PubMed]

[31]. Loh, G.O.K.; Tan, Y.T.F.; Peh, K.K. Hydrophilic Polymer Solubilization on Norfloxacin Solubility in Preparation of Solid Dispersion. Powder Technol. 2014, 256, 462–469. [Google Scholar] [CrossRef]

[32]. Bugay, D.E. Characterization of the Solid-State: Spectroscopic Techniques. Adv. Drug Deliv. Rev. 2001, 48, 43–65. [Google Scholar] [CrossRef] [PubMed]

[33]. Furuyama, N.; Hasegawa, S.; Hamaura, T.; Yada, S.; Nakagami, H.; Yonemochi, E.; Terada, K. Evaluation of Solid Dispersions on a Molecular Level by the Raman Mapping Technique. Int. J. Pharm. 2008, 361, 12–18. [Google Scholar] [CrossRef]

[34]. Sinclair, W.; Leane, M.; Clarke, G.; Dennis, A.; Tobyn, M.; Timmins, P. Physical Stability and Recrystallization Kinetics of Amorphous Ibipinabant Drug Product by Fourier Transform Raman Spectroscopy. J. Pharm. Sci. 2011, 100, 4687–4699. [Google Scholar] [CrossRef]

[35]. Kanaujia, P.; Lau, G.; Ng, W.K.; Widjaja, E.; Schreyer, M.; Hanefeld, A.; Fischbach, M.; Saal, C.; Maio, M.; Tan, R.B.H. Investigating the Effect of Moisture Protection on Solid-State Stability and Dissolution of Fenofibrate and Ketoconazole Solid Dispersions Using PXRD, HSDSC and Raman Microscopy. Drug Dev. Ind. Pharm. 2011, 37, 1026–1035. [Google Scholar] [CrossRef]

[36]. Chen, Y.; Liu, C.; Chen, Z.; Su, C.; Hageman, M.; Hussain, M.; Haskell, R.; Stefanski, K.; Qian, F. Drug–Polymer–Water Interaction and Its Implication for the Dissolution Performance of Amorphous Solid Dispersions. Mol. Pharm. 2015, 12, 576–589. [Google Scholar] [CrossRef]

[37]. Ticehurst, M.D.; Basford, P.A.; Dallman, C.I.; Lukas, T.M.; Marshall, P.V.; Nichols, G.; Smith, D. Characterisation of the Influence of Micronisation on the Crystallinity and Physical Stability of Revatropate Hydrobromide. Int. J. Pharm. 2000, 193, 247–259. [Google Scholar] [CrossRef] [PubMed]

[38]. Enose, A.A.; Dasan, P.K.; Sivaramakrishnan, H.; Shah, S.M. Formulation and Characterization of Solid Dispersion Prepared by Hot Melt Mixing: A Fast Screening Approach for Polymer Selection. J. Pharm. 2014, 2014, 105382. [Google Scholar] [CrossRef] [PubMed]

[39]. Punčochová, K.; Heng, J.Y.Y.; Beránek, J.; Štěpánek, F. Investigation of Drug–Polymer Interaction in Solid Dispersions by Vapour Sorption Methods. Int. J. Pharm. 2014, 469, 159–167. [Google Scholar] [CrossRef] [PubMed]

[40]. Lane, R.A.; Buckton, G. The Novel Combination of Dynamic Vapour Sorption Gravimetric Analysis and near Infra-Red Spectroscopy as a Hyphenated Technique. Int. J. Pharm. 2000, 207, 49–56. [Google Scholar] [CrossRef] [PubMed]

[41]. Paudel, A.; Geppi, M.; Mooter, G. Van den Structural and Dynamic Properties of Amorphous Solid Dispersions: The Role of Solid-State Nuclear Magnetic Resonance Spectroscopy and Relaxometry. J. Pharm. Sci. 2014, 103, 2635–2662. [Google Scholar] [CrossRef] [PubMed]

[42]. Yuan, X.; Sperger, D.; Munson, E.J. Investigating Miscibility and Molecular Mobility of Nifedipine-PVP Amorphous Solid Dispersions Using Solid-State NMR Spectroscopy. Mol. Pharm. 2014, 11, 329–337. [Google Scholar] [CrossRef] [PubMed]
[43]. Litvinov, V.M.; Guns, S.; Adriaensens, P.; Scholtens, B.J.R.; Quaedflieg, M.P.; Carleer, R.; Van den Mooter, G. Solid State Solubility of Miconazole in Poly[(Ethylene Glycol)-g-Vinyl Alcohol] Using Hot-Melt Extrusion. Mol. Pharm. 2012, 9, 2924–2932. [Google Scholar] [CrossRef]
[44]. Ito, A.; Watanabe, T.; Yada, S.; Hamaura, T.; Nakagami, H.; Higashi, K.; Moribe, K.; Yamamoto, K. Prediction of Recrystallization Behavior of Troglitazone/Polyvinylpyrrolidone Solid Dispersion by Solid-State NMR. Int. J. Pharm. 2010, 383, 18–23. [Google Scholar] [CrossRef]
[45]. Dahlberg, C.; Millqvist-Fureby, A.; Schuleit, M.; Furó, I. Relationships between Solid Dispersion Preparation Process, Particle Size and Drug Release—An NMR and NMR Microimaging Study. Eur. J. Pharm. Biopharm. 2010, 76, 311–319. [Google Scholar] [CrossRef]
[46]. Ho, R.; Heng, J.Y.Y. A Review of Inverse Gas Chromatography and Its Development as a Tool to Characterize Anisotropic Surface Properties of Pharmaceutical Solids. KONA Powder Part. J. 2013, 30, 164–180. [Google Scholar] [CrossRef] [Green Version]
[47]. Buckton, G.; Gill, H. The Importance of Surface Energetics of Powders for Drug Delivery and the Establishment of Inverse Gas Chromatography. Adv. Drug Deliv. Rev. 2007, 59, 1474–1479. [Google Scholar] [CrossRef] [PubMed]
[48]. Sun, Y.; Zhu, L.; Wu, T.; Cai, T.; Gunn, E.M.; Yu, L. Stability of Amorphous Pharmaceutical Solids: Crystal Growth Mechanisms and Effect of Polymer Additives. AAPS J. 2012, 14, 380–388. [Google Scholar] [CrossRef] [PubMed]
[49]. Hasegawa, S.; Ke, P.; Buckton, G. Determination of the Structural Relaxation at the Surface of Amorphous Solid Dispersion Using Inverse Gas Chromatography. J. Pharm. Sci. 2009, 98, 2133–2139. [Google Scholar] [CrossRef] [PubMed]
[50]. Miyanishi, H.; Nemoto, T.; Mizuno, M.; Mimura, H.; Kitamura, S.; Iwao, Y.; Noguchi, S.; Itai, S. Evaluation of Crystallization Behavior on the Surface of Nifedipine Solid Dispersion Powder Using Inverse Gas Chromatography. Pharm. Res. 2013, 30, 502–511. [Google Scholar] [CrossRef] [PubMed]